Pasithea therapeutics announces invention of crystalline form of pas-004; establishes strengthened intellectual property (ip) position

-- polymorph and stereoisomer patents when issued extend portfolio to at least 2045 -- -- polymorph and stereoisomer patent filings continue to expand patent portfolio -- south san francisco, calif. and miami, jan. 08, 2024 (globe newswire) -- pasithea therapeutics corp. (nasdaq: ktta) (“pasithea” or the “company”), a clinical stage biotechnology company focused on the discovery, research, and development of innovative treatments for central nervous system (cns) disorders, today announced the invention of a crystalline form of pas-004 which is captured in polymorph and stereoisomer patent filings that when issued we believe will extend patent protection to at least 2045.
KTTA Ratings Summary
KTTA Quant Ranking